Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL4752940

CON=C(C(=O)O)c1ccco1.N

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
PTPN1 P18031 1/20 0.50
SMN1; SMN2 Q16637 7/20 0.49
TDP1 Q9NUW8 3/20 0.49
PKM P14618 3/20 0.44
ERCC5 P28715 1/20 0.44
FEN1 P39748 1/20 0.44
RAB9A P51151 5/20 0.43
NPC1 O15118 4/20 0.43
POLB P06746 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KMT2A Q03164 3/20 0.42
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
THRB P10828 1/20 0.41
APEX1 P27695 1/20 0.41
RECQL P46063 1/20 0.41
MAOB P27338 2/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL28417876 1.00 CES2 (0.50) CES2CES1PTPN1SMN1; SMN2TDP1
Ammonia Solution, Strong SCHEMBL5211578 1.00 CES2 (0.50) CES2CES1PTPN1SMN1; SMN2TDP1
SCHEMBL2812477 0.98 CES2 (0.52) CES2CES1PTPN1SMN1; SMN2TDP1
SCHEMBL4609969 0.98 CES2 (0.52) CES2CES1PTPN1SMN1; SMN2TDP1
SCHEMBL11457463 0.98 CES2 (0.52) CES2CES1PTPN1SMN1; SMN2TDP1
SCHEMBL13983961 0.85 CES2 (0.52) CES2CES1PTPN1SMN1; SMN2TDP1
SCHEMBL5217865 0.83 CES2 (0.50) CES2CES1PTPN1SMN1; SMN2TDP1
SCHEMBL12180935 0.83 CES2 (0.50) CES2CES1PTPN1SMN1; SMN2TDP1
SCHEMBL9634783 0.83 CES2 (0.55) CES2CES1PTPN1SMN1; SMN2TDP1
SCHEMBL3729528 0.83 CES2 (0.50) CES2CES1PTPN1SMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117587472-A Electroplating solution for through blind hole co-plating and application thereof and method for through blind hole co-plating of HDI board 上海天承化学有限公司 2024-02-23 CN claimed
CN-106366098-A Cefuroxime sodium compound prepared through advanced on-line process control technology and preparation thereof 陕西顿斯制药有限公司 2017-02-01 CN claimed
CN-117587472-A Electroplating solution for through blind hole co-plating and application thereof and method for through blind hole co-plating of HDI board 上海天承化学有限公司 2024-02-23 CN disclosed
CN-106187960-B A kind of preparation method of 2- methoxyiminos -2- furyl acetic acid ammonium salts 四平市精细化学品有限公司 2018-08-14 CN disclosed
CN-106366098-A Cefuroxime sodium compound prepared through advanced on-line process control technology and preparation thereof 陕西顿斯制药有限公司 2017-02-01 CN disclosed
CN-106187960-A A kind of preparation method of 2 methoxyimino 2 furyl acetic acid ammonium salts 四平市精细化学品有限公司 2016-12-07 CN disclosed
WO-2008155615-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF CEPHALOSPORIN ANTIBIOTIC ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2008-12-24 WO disclosed
US-20070275954-A1 Novel Fused Heterocycles and Uses Thereof ASTRAZENECA AB (SE) 2007-11-29 US disclosed
EP-1751119-A1 NOVEL FUSED HETEROCYCLES AND USES THEREOF AstraZeneca AB (SE) 2007-02-14 EP disclosed
WO-2005111001-A1 NOVEL FUSED HETEROCYCLES AND USES THEREOF ASTRAZENECA AB (SE) 2005-11-24 WO disclosed
WO-2004050663-A2 AN IMPROVED PROCESS FOR THE PREPARATION OF CEFUROXIME SODIUM ORCHID CHEMICALS & PHARMACEUTICALS LTD (IN) 2004-06-17 WO disclosed
WO-2004041831-A1 AN IMPROVED PROCESS FOR THE PREPARATION OF CEFUROXIME SODIUM ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2004-05-21 WO disclosed
US-20040092735-A1 Process for the preparation of cefuroxime sodium ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) 2004-05-13 US disclosed
US-4876351-A Process for the separation of a mixture of \"syn\" and \"anti\" oxime isomers GLAXO GROUP LIMITED (GB) 1989-10-24 US disclosed
US-4717768-A Process for separation of syn and anti oxime isomers of cephalosporin-compounds GLAXO GROUP LIMITED (GB) 1988-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092735-A1 Process for the preparation of cefuroxime sodium CYP2F1, CYP51A1, CYP17A1 CES2 1088/4885CES1 113/4885PTPN1 1363/4885
US-20070275954-A1 Novel Fused Heterocycles and Uses Thereof VIP, CCKBR, HRH2 CES2 1687/4885CES1 1016/4885PTPN1 3794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.